Novoprotein(SH:688137)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥36,017,741.43, a decrease of 22.20% compared to the same period last year, and a cumulative revenue of ¥110,706,893.65, down 47.93% year-to-date[5] - The net profit attributable to shareholders for Q3 2023 was ¥3,516,357.06, down 81.30% year-on-year, with a year-to-date net profit of ¥15,876,672.69, down 82.38%[5] - The net profit after deducting non-recurring gains and losses for Q3 2023 was -¥702,251.31, a decrease of 104.03%, and -¥938,692.65 year-to-date, down 101.08%[5] - Total operating revenue for the first three quarters of 2023 was CNY 110,706,893.65, a decrease from CNY 212,629,893.17 in the same period of 2022, representing a decline of approximately 48%[22] - Net profit for the third quarter of 2023 was CNY 15,876,672.69, down from CNY 90,105,051.52 in the same quarter of 2022, reflecting a decrease of approximately 82%[23] - In Q3 2023, the company's total comprehensive income amounted to CNY 15,867,037.47, a significant decrease from CNY 90,094,143.97 in the same period last year[24] - Basic and diluted earnings per share for Q3 2023 were CNY 0.23, down from CNY 1.71 in Q3 2022[24] Expenses and Investments - Research and development expenses totaled ¥11,899,314.57 in Q3 2023, an increase of 13.60%, and accounted for 33.04% of operating revenue, up 10.41 percentage points[6] - Research and development expenses for the first three quarters of 2023 were CNY 37,204,713.45, compared to CNY 28,484,447.30 in the same period of 2022, showing an increase of approximately 30%[22] - The company reported a significant increase in sales expenses, which rose to CNY 33,303,697.28 in 2023 from CNY 20,745,404.02 in 2022, marking an increase of about 60%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,300,876,075.46, a decrease of 1.60% from the end of the previous year[6] - The total assets as of the end of the third quarter of 2023 were CNY 2,300,876,075.46, slightly down from CNY 2,338,298,078.50 at the end of the previous quarter[18] - Total liabilities decreased to CNY 115,585,468.17 in the third quarter of 2023 from CNY 138,911,832.07 in the same quarter of 2022, a reduction of about 17%[18] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥51,739,786.35, reflecting an increase of 422.71%[6] - Cash inflow from operating activities for the first nine months of 2023 was CNY 219,326,523.12, slightly up from CNY 213,337,132.17 in the same period of 2022[26] - Net cash flow from operating activities in Q3 2023 was CNY 51,739,786.35, a substantial increase compared to CNY 9,898,324.44 in Q3 2022[27] - The company reported cash inflow from investment activities of CNY 3,081,445,483.18 in the first nine months of 2023, compared to CNY 9,900.00 in the same period last year[27] - Net cash flow from investment activities was CNY 711,035,892.80, a turnaround from a negative CNY 262,439,445.66 in the previous year[27] - The company experienced a net cash outflow from financing activities of CNY 51,368,607.46 in Q3 2023, contrasting with a net inflow of CNY 1,759,361,950.49 in Q3 2022[28] Shareholder Information - The company reported a total of 7,589 common shareholders at the end of the reporting period[13] - The largest shareholder, Shanghai Xinbainuo Biotechnology Co., Ltd., holds 30,355,000 shares, representing 43.26% of total shares[13] Government Support - The company received government subsidies amounting to ¥2,039,807.00 in Q3 2023, contributing to its financial performance[8] Market and Strategic Outlook - The company reported a significant decline in pandemic prevention product sales, impacting overall revenue, while conventional business sales grew by 15.13% year-on-year[7] - The company is focusing on strategic adjustments and market expansion to address the declining revenue trend and improve profitability in the upcoming quarters[22] - The company has not reported any significant new product developments or technological advancements in the current quarter[15] - There are no updates on market expansion or mergers and acquisitions in the latest report[15] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[15] - The report indicates that there are no significant changes in the shareholder structure or related party transactions[15]